查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1850471

骨關節炎治療市場按治療類型、給藥途徑、最終用戶和分銷管道分類－全球預測，2025-2032年

Osteoarthritis Therapeutics Market by Treatment Type, Route of Administration, End-User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，骨關節炎治療市場規模將達到 93.5 億美元，複合年成長率為 7.68%。

關鍵市場統計數據
基準年 2024 51.7億美元
預計年份：2025年 55.5億美元
預測年份 2032 93.5億美元
複合年成長率 (%) 7.68%

本書對當前骨關節炎治療模式和不斷發展的多學科治療路徑進行了簡明扼要、權威的概述，旨在為相關人員的決策提供參考。

骨關節炎仍然是最常見的退化性關節疾病之一，因此臨床上持續關注並進行多學科創新，旨在緩解疼痛、恢復功能並延緩或避免侵入性手術。近年來，治療方法日趨融合，涵蓋了從保守療法和輔助療法到先進的外科手術，這反映出以患者為中心的治療理念正朝著個體化護理路徑轉變，力求在控制症狀和長期保護關節之間取得平衡。臨床醫生、支付方和醫療保健提供者越來越重視多學科管理，將藥物治療、物理治療、生活方式干涉和選擇性手術治療相結合，以最佳化療效並最大限度地減少副作用。

同時，技術賦能的醫療模式和數位療法拓展了臨床醫生和患者可用的套件，實現了大規模的遠端監測、依從性支持和復健。這些發展帶來了新的機會和挑戰，因為整個生態系統中的相關人員必須兼顧臨床療效、報銷動態和病患偏好。重要的是，監管和安全考量將繼續影響特定藥物類別和關節內療法的應用，因此需要強力的證據支持和上市後監測。

隨著醫療保健系統將重點放在以價值為導向的醫療服務和長期療效上，骨關節炎治療的策略規劃需要對治療路徑、給藥途徑以及提供醫療服務的機構有深入的了解。本執行摘要總結了當前趨勢、結構性變化和可操作的見解，旨在為製藥、醫療技術和醫療服務機構的研發優先排序、產品組合管理和商業策略提供參考。

這是重塑骨關節炎治療模式的關鍵曲折點，包括整合多模態治療、生技藥品、數位化復健和以價值主導的報銷機制。

骨關節炎的治療格局正在經歷多項變革，這些變革正在重塑臨床實踐和商業策略。首先，治療模式正明顯轉向多模態治療，將針灸、按摩療法和營養補充劑等輔助療法與傳統藥物治療和針對性手法治療相結合。這種綜合模式充分考慮了患者病情的多樣性，並強調制定個人化的治療方案，以減少對長期服用全身性止痛藥物的依賴。

其次，生物製藥和器械治療方法的進步正在提升局部治療的作用，包括複雜的關節內注射和微創手術。這些治療方法旨在以更少的全身暴露緩解症狀，其應用受到新興臨床證據、支付方政策以及門診和日間手術能力的影響。第三，數位醫療和遠距復健平台正在擴大患者獲得物理治療和自我管理計畫的途徑，改變患者參與和依從性的模式，並使醫療服務提供者能夠將護理範圍擴展到傳統的實體診療之外。

第四，支付方和採購策略日益關注療效和成本效益，獎勵那些能夠顯著降低後續資源利用率的醫療模式，例如減少醫院再入院和早期關節關節重建。最後，涵蓋製藥公司、醫療設備製造商、數位醫療供應商和專科診所的跨產業合作正在推動新型商業夥伴關係和打包式醫療服務模式的出現。這些轉變需要製定適應性策略，使臨床證據的產生與新的醫療服務模式和不斷發展的報銷框架相契合。

評估2025年關稅調整和貿易政策變化將如何改變骨關節炎治療藥物的供應鏈、採購經濟效益和商業化時間表

近期有關關稅和貿易的政策發展可能會對骨關節炎治療格局產生重大影響，因為這會影響進口到美國的醫療設備、植入和某些藥品原料的投入成本。對醫療設備和用於製造植入、關節鏡檢查設備以及某些注射藥物的原料徵收更高的關稅，可能會導致供應商的到岸成本上升，從而可能迫使製造商重新評估其籌資策略、供應商多元化和區域製造地。因此，在談判設備採購和植入物合約時，醫院和診所可能會面臨壓力，需要爭取更高的價值、延長採購週期，並在可能的情況下優先考慮國內替代方案。

此外，關稅可能導致短期供應鏈波動，影響醫院藥房、零售店和銷售骨關節炎治療藥物的線上藥局的庫存計劃。供應商通常會在預期成本上升時調整定價策略、改變與經銷商的談判方式，或選擇性地降低其產品組合的利潤，這可能會影響產品的供應和促銷投入。對於新藥公司和小型製造商而言，關稅主導的成本上漲可能會提高進入門檻並延緩商業化進程，尤其對於資本密集醫療設備的上市和依賴特殊組件的複雜生物製藥。

為此，許多相關人員正在加速推進供應鏈韌性計劃，包括近岸外包、雙重採購和長期供應商協議，以降低關稅波動帶來的風險。醫療系統和集團採購組織的策略性應對措施包括情境規劃，該規劃整合了採購彈性、應對投入成本波動的合約條款以及在控制成本的同時維持醫療品質的臨床替代路徑。最終，2025年關稅變化帶來的累積影響凸顯了製定綜合商業和供應鏈策略的必要性，這些策略既能保障治療藥物和醫療設備的可及性，又能促進創新。

透過全面的細分，將治療方式、給藥途徑、醫療機構環境和分銷管道與臨床和商業性應用促進因素聯繫起來，主導洞察。

細緻的市場區隔框架揭示了不同治療類型、給藥途徑、最終用戶和分銷管道的獨特需求促進因素、護理路徑和商業性需求。根據治療類型，市場包括針灸、按摩療法和營養補充劑等輔助療法，以及皮質類固醇注射、透明質酸注射、非類固醇消炎劑和鴉片類藥物等藥物療法。每種治療方法的證據閾值、患者接受動態和報銷情況各不相同，這些因素都會影響其普及曲線和醫療服務提供者的獎勵。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 評估一種針對神經生長因子的新型單株抗體療法在治療骨關節炎疼痛的療效
  • 引入再生醫學方法，例如間質幹細胞注射，用於治療膝骨關節炎
  • 整合穿戴式感測器數據的數位健康平台對骨關節炎個人化治療方案的影響
  • 骨關節炎治療中關節內基因治療產品的監管核准途徑與安全性問題
  • 在骨關節炎早期階段推廣微骨折和支架式軟骨修復技術
  • 為推進骨關節炎治療決策中的真實世界證據，對患者報告結局指標的需求日益成長
  • 開發針對發炎細胞激素的新型小分子抑制劑，以延緩骨關節炎的進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療類型分類的骨關節炎治療市場

  • 輔助療法
    • 針刺
    • 按摩療法
    • 營養補充品
  • 藥物治療
    • 皮質類固醇注射
    • 玻尿酸注射
    • 非類固醇消炎劑（NSAIDs）
    • 鴉片類藥物
  • 物理治療
  • 外科手術
    • 關節鏡
    • 關節重建
    • 截骨術
      • 股骨截骨術
      • 脛骨截骨術

9. 依給藥途徑分類的骨關節炎治療市場

  • 注射
  • 口服
  • 外用
  • 經皮

第10章 依最終用戶分類的骨關節炎治療市場

  • 診所
  • 醫院
  • 復健中心

第11章 骨關節炎治療市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 各地區骨關節炎治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 依組別分類的骨關節炎治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國骨關節炎治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Cipla Ltd.
    • Eli Lilly and Company
    • Endo International plc
    • Ferring BV
    • Fidia Farmaceutici SpA
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services Inc.
    • Merck & Co.
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.
Product Code: MRR-DD6333AE50BA

The Osteoarthritis Therapeutics Market is projected to grow by USD 9.35 billion at a CAGR of 7.68% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.17 billion
Estimated Year [2025] USD 5.55 billion
Forecast Year [2032] USD 9.35 billion
CAGR (%) 7.68%

A concise and authoritative overview of current osteoarthritis therapeutic paradigms and evolving multidisciplinary care pathways shaping stakeholder decision-making

Osteoarthritis remains one of the most prevalent degenerative joint disorders, driving sustained clinical attention and cross-sector innovation aimed at alleviating pain, restoring function, and delaying or avoiding invasive procedures. Recent years have seen a convergence of therapeutic approaches that span conservative complementary modalities through to advanced surgical interventions, reflecting a patient-centric shift toward personalized care pathways that balance symptom control with long-term joint preservation. Clinicians, payers, and providers increasingly emphasize multidisciplinary management, combining pharmacologic options with physical therapy, lifestyle interventions, and selective procedural therapies to optimize outcomes while minimizing adverse effects.

Concurrently, technology-enabled care models and digital therapeutics have expanded the toolkit available to clinicians and patients, enabling remote monitoring, adherence support, and rehabilitation at scale. These developments create new opportunities and complexities for stakeholders across the ecosystem, as they must reconcile clinical efficacy, reimbursement dynamics, and patient preferences. Importantly, regulatory scrutiny and safety considerations continue to shape the adoption of certain drug classes and intra-articular therapies, necessitating robust evidence generation and post-market surveillance.

As healthcare systems prioritize value-based care and longitudinal outcomes, strategic planning for osteoarthritis therapeutics requires nuanced understanding of treatment pathways, administration routes, and the providers who deliver care. This executive summary synthesizes current trends, structural shifts, and actionable insights that can inform R&D prioritization, portfolio management, and commercial strategies across pharmaceutical, medtech, and service delivery organizations.

Critical inflection points reshaping osteoarthritis treatment models including integration of multimodal care, biologics, digital rehabilitation, and value-driven reimbursement

The landscape of osteoarthritis therapeutics is undergoing several transformative shifts that are recalibrating clinical practice and commercial strategy. First, there is a clear reorientation toward multimodal care that integrates complementary therapies-such as acupuncture, massage therapy, and nutritional supplements-with traditional pharmacologic treatments and targeted procedural approaches. This integrated model acknowledges the heterogeneity of patient presentations and emphasizes individualized care plans that may reduce reliance on long-term systemic analgesics.

Second, advances in biologic and device-based interventions have elevated the role of localized therapies, including refined intra-articular injections and minimally invasive surgical techniques. These modalities aim to achieve symptom relief with lower systemic exposure, and their uptake is influenced by emerging clinical evidence, payer policies, and procedural capacity in outpatient and ambulatory settings. Third, digital health and tele-rehabilitation platforms are scaling access to supervised physical therapy and self-management programs, altering patient engagement and adherence dynamics and enabling providers to extend care beyond traditional brick-and-mortar encounters.

Fourth, payer and procurement strategies are increasingly focused on outcomes and cost-effectiveness, incentivizing care models that demonstrably reduce downstream resource utilization such as hospital readmissions or early joint replacement. Finally, cross-industry collaboration-spanning pharmaceuticals, medical device manufacturers, digital health vendors, and specialty clinics-is driving novel commercial partnerships and bundled care offerings. Together, these shifts demand adaptive strategies that align clinical evidence generation with novel delivery models and evolving reimbursement frameworks.

Assessing how tariff shifts and trade policy adjustments in 2025 can alter supply chains, procurement economics, and commercialization timelines across osteoarthritis therapeutics

Recent policy developments relating to tariffs and trade can exert meaningful influence on the osteoarthritis therapeutics landscape by affecting input costs for devices, implants, and certain pharmaceutical components imported into the United States. Increased duties on medical devices or raw materials used in manufacturing implants, arthroscopy equipment, and certain injectables can lead to higher landed costs for suppliers and may prompt manufacturers to reassess procurement strategies, supplier diversification, and regional manufacturing footprints. In turn, hospitals and clinics negotiating capital purchases and implant contracts may face pressure to extract greater value, extend procurement cycles, or prioritize domestically manufactured alternatives where available.

Moreover, tariffs can create short-term supply chain volatility that impacts inventory planning for hospital pharmacies, retail outlets, and online pharmacies that distribute osteoarthritis therapies. When suppliers anticipate cost headwinds, they often adjust pricing strategies, negotiate differently with distributors, or absorb margins selectively across portfolios, which can influence product availability and promotional investments. For innovators and smaller manufacturers, tariff-driven cost increases can heighten barriers to entry or slow commercialization timelines, particularly for capital-intensive device launches or complex biologic formulations that depend on specialized components.

In response, many stakeholders have accelerated supply chain resilience programs, including nearshoring, dual sourcing, and longer-term supplier agreements to mitigate exposure to tariff volatility. For health systems and group purchasing organizations, a strategic response includes scenario planning that integrates procurement flexibility, contract clauses addressing input-cost variability, and clinical substitution pathways that preserve care quality while managing cost. Ultimately, the cumulative impact of tariff changes in 2025 emphasizes the imperative for integrated commercial and supply chain strategies that protect access while sustaining innovation across therapeutics and devices.

Comprehensive segmentation-driven insights that map treatment modalities, administration routes, provider settings, and distribution channels to clinical and commercial adoption drivers

A nuanced segmentation framework illuminates distinct demand drivers, care pathways, and commercial imperatives across treatment type, route of administration, end-user, and distribution channel. Based on treatment type, the market comprises complementary therapies that include acupuncture, massage therapy, and nutritional supplements alongside drug therapy spanning corticosteroid injections, hyaluronic acid injections, non-steroidal anti-inflammatory drugs, and opioids; physical therapy modalities remain central to conservative management; and surgical solutions encompass arthroscopy, joint replacement, and osteotomy with femoral and tibial osteotomy subtypes that require distinct surgical expertise and implant considerations. Each of these treatment pathways has different evidence thresholds, patient acceptance dynamics, and reimbursement profiles, which in turn influence adoption curves and provider incentives.

Based on route of administration, therapies arrive via injectable, oral, topical, and transdermal pathways, with injectables attracting attention for their targeted delivery and potential for reduced systemic exposure, while oral and topical agents remain important for broad symptom management and ease of use. Based on end-user, clinics, hospitals, and rehabilitation centers each serve differentiated roles: clinics and outpatient centers emphasize access and conservative care delivery, hospitals provide surgical and acute interventions, and rehabilitation centers focus on intensive post-procedural recovery and functional restoration. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies mediate how therapies reach patients, with each channel presenting unique considerations around inventory management, cold-chain logistics for certain injectables, patient counseling, and reimbursement coding.

Taken together, this segmentation underscores that product development, clinical trial design, and commercial planning must align with the practical realities of administration route, provider capabilities, and distribution pathways. Transitioning from clinical proof-of-concept to widespread adoption often requires tailored evidence packages, clinician education, and distribution agreements calibrated to the dominant channels serving target patient cohorts.

Regional strategic considerations tying patient demographics, reimbursement frameworks, and clinical infrastructure to differentiated adoption pathways across global markets

Regional dynamics shape access, adoption, and strategic priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct clinical infrastructures, reimbursement frameworks, and patient demographics. In the Americas, integrated health systems and private sector innovation support rapid uptake of minimally invasive procedures and advanced injectables, while payer negotiation and value-based contracting increasingly determine coverage decisions and formulary placement. Conversely, Europe, Middle East & Africa exhibit heterogeneous regulatory landscapes and procurement models; this region combines markets with high procedural capacity and sophisticated payers alongside settings where cost containment and access gaps emphasize conservative care and scalable rehabilitation solutions.

Asia-Pacific presents a diverse mix of highly innovative markets with strong manufacturing capabilities and rapidly growing clinical volumes alongside emerging healthcare systems investing in surgical capacity and rehabilitation services. Across all regions, demographic shifts toward aging populations and rising prevalence of osteoarthritis amplify demand for effective, durable interventions and scalable care pathways. Regional reimbursement nuances influence the prioritization of certain therapies, with some payers favoring interventions demonstrating demonstrable reductions in downstream surgical interventions and others prioritizing short-term cost containment.

Given these regional contours, manufacturers and service providers must tailor market entry strategies, evidence generation plans, and commercial models to local regulatory expectations, distribution norms, and provider reimbursement incentives. Strategic partnerships with regional distributors, capacity-building programs for surgeons and rehabilitation teams, and differentiated pricing strategies are critical levers to bridge clinical innovation with sustainable access across diverse geographies.

Competitive and innovation-focused intelligence revealing how clinical evidence, partnerships, and service models are redefining leadership in osteoarthritis therapeutics

Competitive dynamics within osteoarthritis therapeutics reflect a blend of established incumbents and agile challengers, with differentiation increasingly driven by the strength of clinical evidence, pathway integration capabilities, and service-enablement. Leading pharmaceutical and device organizations continue to invest in incremental innovation-refinements to injectables, implant materials, and surgical instrumentation-while newer entrants emphasize disruptive approaches such as regenerative therapies, novel biologics, and digitally enabled rehabilitation platforms. Partnerships and alliances between manufacturers, specialty clinics, and digital vendors are accelerating commercial reach and enabling bundled care propositions that align clinical outcomes with payer value goals.

R&D pipelines emphasize improved safety profiles, targeted delivery, and longer durability of effect, with clinical programs designed to generate real-world evidence that supports favorable reimbursement decisions. For surgical device makers and implant suppliers, manufacturing scale, cost-efficient supply chains, and service models that support surgeon training and OR efficiency have become competitive differentiators. At the same time, distributors and pharmacy channels are optimizing logistics and patient services to support therapy adherence and home-based care models.

Strategic M&A activity and licensing deals have favored entities that can complement broader portfolios with specialty devices, high-value biologics, or digital infrastructure that enhances long-term patient monitoring. For commercial leaders, the priority is to align product positioning with provider workflows and payer benchmarks, invest in clinician education to accelerate uptake, and deploy health economics evidence that articulates the value proposition in terms of patient outcomes and resource utilization.

Actionable strategic measures for manufacturers, providers, and payers to accelerate evidence-informed adoption, secure reimbursement, and strengthen supply chain resilience

Industry leaders should pursue a set of pragmatic, high-impact actions to navigate the current osteoarthritis therapeutics landscape and capture sustainable value. First, align clinical development with pragmatic endpoints that matter to payers and providers, including measures of functional improvement, durability of effect, and impact on downstream surgical rates, while integrating real-world evidence generation into post-approval plans to support reimbursement and uptake. Second, design commercialization strategies that match distribution channels and end-user needs: ensure hospital pharmacy readiness for specialty injectables, support online pharmacy patient services for outpatient therapies, and partner with clinics and rehabilitation centers to embed multimodal care pathways.

Third, invest in supply chain resilience and cost containment measures to mitigate exposure to tariff-related cost volatility and component shortages, including dual sourcing, regional manufacturing, and long-term supplier agreements. Fourth, develop bundled service offerings and clinician training programs that reduce barriers to adoption for novel surgical techniques and device platforms, and leverage digital rehabilitation and remote monitoring to extend patient engagement beyond the clinic. Fifth, cultivate payer engagement early to negotiate coverage pathways and value-based contracting that reflect long-term outcomes. Finally, prioritize cross-functional collaboration across R&D, commercial, regulatory, and supply chain teams to ensure coordinated launch execution and to adapt rapidly to evolving clinical evidence and reimbursement landscapes.

A rigorous, triangulated research methodology combining clinical evidence review, stakeholder interviews, and distribution channel analysis to underpin strategic recommendations

This analysis synthesizes insights derived from a triangulated research methodology combining structured literature review, expert interviews, and channel analysis to ensure both depth and practical relevance. The structured literature component encompassed peer-reviewed clinical studies, regulatory guidance, and specialty society recommendations to ground therapeutic claims in contemporary clinical evidence. Expert interviews with clinicians, procurement leaders, and commercial executives provided contextual understanding of adoption barriers, procedural trends, and payer negotiation dynamics, while channel analysis examined distribution nuances across hospital pharmacies, online pharmacies, and retail pharmacies to reflect the logistics and patient access implications of different therapies.

Where applicable, public regulatory filings and clinical trial registries informed assessment of pipeline priorities and safety considerations. The methodology emphasized cross-validation across data sources to enhance reliability and minimize bias, and findings were reviewed by practicing clinicians and industry experts to ensure practical applicability. Limitations of the research approach include heterogeneity in reporting standards across geographies and the evolving nature of tariff and trade policy, which necessitates ongoing monitoring. Nevertheless, the methodology provides a robust foundation for strategic decision-making by combining empirical clinical evidence, stakeholder perspectives, and operational channel insights.

Concluding synthesis that crystallizes strategic imperatives linking clinical evidence, distribution readiness, and operational resilience to long-term success in osteoarthritis care

In conclusion, osteoarthritis therapeutics occupy a dynamic intersection of clinical need, technological innovation, and evolving care delivery models. Stakeholders that successfully bridge robust clinical evidence with pragmatic commercial strategies-attuned to route of administration, provider settings, and distribution realities-will be best positioned to deliver differentiated value to patients and payers. The interplay of complementary therapies, targeted drug interventions, physical therapy, and surgical techniques underscores the necessity of integrated care pathways that are adaptable to patient heterogeneity and regional system constraints.

Supply chain resilience and strategic responses to tariff pressures will remain important operational considerations, particularly for devices and components with complex sourcing profiles. Competitive leadership will favor organizations that combine credible outcomes data, clinician engagement programs, and distribution capabilities across hospital, online, and retail channels. Ultimately, the most effective approaches are those that align product and service design with measurable improvements in patient function and quality of life while providing clear economic value to payers and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Evaluation of emerging monoclonal antibody therapies targeting nerve growth factor in osteoarthritis pain management
  • 5.2. Adoption of regenerative medicine approaches such as mesenchymal stem cell injections in knee osteoarthritis treatment landscape
  • 5.3. Impact of digital health platforms integrating wearable sensor data for personalized osteoarthritis treatment plans
  • 5.4. Regulatory approval pathways and safety concerns for intra-articular gene therapy products in osteoarthritis management
  • 5.5. Expansion of micro-fracture and scaffold-based cartilage repair techniques in early-stage osteoarthritis patients
  • 5.6. Rising demand for patient-reported outcome measures to drive real-world evidence in osteoarthritis therapeutic decision-making
  • 5.7. Development of novel small-molecule inhibitors targeting inflammatory cytokines in osteoarthritis progression

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoarthritis Therapeutics Market, by Treatment Type

  • 8.1. Complementary Therapies
    • 8.1.1. Acupuncture
    • 8.1.2. Massage Therapy
    • 8.1.3. Nutritional Supplements
  • 8.2. Drug Therapy
    • 8.2.1. Corticosteroid Injections
    • 8.2.2. Hyaluronic Acid Injections
    • 8.2.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.2.4. Opioids
  • 8.3. Physical Therapy
  • 8.4. Surgery
    • 8.4.1. Arthroscopy
    • 8.4.2. Joint Replacement
    • 8.4.3. Osteotomy
      • 8.4.3.1. Femoral Osteotomy
      • 8.4.3.2. Tibial Osteotomy

9. Osteoarthritis Therapeutics Market, by Route of Administration

  • 9.1. Injectable
  • 9.2. Oral
  • 9.3. Topical
  • 9.4. Transdermal

10. Osteoarthritis Therapeutics Market, by End-User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Rehabilitation Centers

11. Osteoarthritis Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Osteoarthritis Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Osteoarthritis Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Osteoarthritis Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. AbbVie Inc.
    • 15.3.2. Amgen Inc.
    • 15.3.3. AstraZeneca PLC
    • 15.3.4. Bayer AG
    • 15.3.5. Boehringer Ingelheim International GmbH
    • 15.3.6. Cipla Ltd.
    • 15.3.7. Eli Lilly and Company
    • 15.3.8. Endo International plc
    • 15.3.9. Ferring B.V.
    • 15.3.10. Fidia Farmaceutici S.p.A
    • 15.3.11. GlaxoSmithKline PLC
    • 15.3.12. Johnson & Johnson Services Inc.
    • 15.3.13. Merck & Co.
    • 15.3.14. Pfizer Inc.
    • 15.3.15. Sanofi S.A.
    • 15.3.16. Sun Pharmaceutical Industries Ltd.
    • 15.3.17. Teva Pharmaceutical Industries Ltd.
    • 15.3.18. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. OSTEOARTHRITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. OSTEOARTHRITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. OSTEOARTHRITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ACUPUNCTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY MASSAGE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OPIOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ARTHROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY JOINT REPLACEMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY FEMORAL OSTEOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TIBIAL OSTEOTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REHABILITATION CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY COMPLEMENTARY THERAPIES, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY DRUG THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY SURGERY, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, BY OSTEOTOMY, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA O